{"links":{"html":"https://www.erudio.com/reports/pe-pe-nct05578664","json":"https://www.erudio.com/reports/pe-pe-nct05578664.json","markdown":"https://www.erudio.com/reports/pe-pe-nct05578664.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"pe-pe-05578664"}},"request":"https://www.erudio.com/contact?report=pe-pe-05578664"},"offer":{"cited_commentary_sources":13,"verified_hcp_statements":35,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":13,"optional":true,"price_per_verified_person_usd":15,"price_usd":195,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"pe-pe-nct05578664"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=pe-pe-05578664","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/pe-pe-nct05578664","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-29T20:03:43.852812Z","notify_subscribers":false,"status":"corrected","summary":"Corrected to match the delivered report: the limitations; the sample findings. The page names the trial's tested drugs (pembrolizumab) and indication (oligometastatic renal cell carcinoma)."},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":13,"no_commentary_found":0},"aspects":[{"claim_count":10,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":8,"title":"Primary endpoint: Relapsed Free Survival (RFS)"},{"claim_count":3,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes[0]","source_count":2,"title":"Secondary endpoint: Distant Relapsed Free Survival (Distant RFS)"},{"claim_count":2,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes[1]","source_count":2,"title":"Secondary endpoint: Overall Survival (OS)"},{"claim_count":5,"coverage":"discussed","id":"T4","registry_field":"outcomesModule.secondaryOutcomes[2]","source_count":5,"title":"Secondary endpoint: Safety Endpoint"},{"claim_count":1,"coverage":"discussed","id":"T5","registry_field":"outcomesModule.secondaryOutcomes[3]","source_count":1,"title":"Secondary endpoint: Local Progression Disease (Local PD)"},{"claim_count":11,"coverage":"discussed","id":"T6","registry_field":"conditionsModule","source_count":6,"title":"Population and setting"},{"claim_count":15,"coverage":"discussed","id":"T7","registry_field":"armsInterventionsModule.armGroups","source_count":7,"title":"The comparison"},{"claim_count":5,"coverage":"discussed","id":"T8","registry_field":"outcomesModule","source_count":5,"title":"Safety and tolerability"},{"claim_count":9,"coverage":"discussed","id":"T9","registry_field":"designModule","source_count":4,"title":"Design and conduct"},{"claim_count":2,"coverage":"discussed","id":"A1","source_count":2,"title":"Selection for systemic-treatment deferral"},{"claim_count":4,"coverage":"discussed","id":"A2","source_count":3,"title":"M1 NED precedent and the relevance of later recurrence"},{"claim_count":3,"coverage":"discussed","id":"A3","source_count":1,"title":"What the comparison does not prove: MDT benefit, synergy and quality of life"},{"claim_count":3,"coverage":"discussed","id":"A4","source_count":2,"title":"Local-treatment technique and prior disease history needed for interpretation"}],"counts":{"cited_sources":14,"claims_by_expression_type":{"comparison":2,"experience":3,"interpretation":6,"opinion":8,"primary_context":2,"question":2,"restatement":9,"uncertainty":3},"claims_by_kind":{"protocol_statement":2,"source_observation":33},"clinician_statements":24,"evidence_units":25,"findings":6,"organisational_accounts":1,"people_cited":14,"people_identity_verified":13,"people_total":14,"screened_sources":30,"verified_claims":35},"findings_index":[{"id":"F1","structure":{"claims":13,"claims_by_group":{"comparisons":0,"experience":1,"questions":0,"restated":5,"views":7},"has_counterview":false,"limitations":3,"links":{"context":1,"support":14},"ma_question":true,"named_voices":6,"passages":8,"sources":6,"sources_by_kind":{"commentary":5,"registry":1}},"title":"Support for adding pembrolizumab is stronger than the evidence for survival, quality of life or treatment-component synergy"},{"id":"F2","structure":{"claims":2,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":2},"has_counterview":false,"limitations":3,"links":{"context":0,"support":2},"ma_question":true,"named_voices":2,"passages":2,"sources":2,"sources_by_kind":{"commentary":2}},"title":"MDT-first systemic-treatment deferral is described as a selective exception"},{"id":"F3","structure":{"claims":6,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":3,"views":3},"has_counterview":false,"limitations":3,"links":{"context":0,"support":6},"ma_question":true,"named_voices":5,"passages":5,"sources":5,"sources_by_kind":{"commentary":5}},"title":"The favorable RFS reading carries a meaningful toxicity qualification"},{"id":"F4","structure":{"claims":9,"claims_by_group":{"comparisons":1,"experience":0,"questions":2,"restated":2,"views":4},"has_counterview":false,"limitations":4,"links":{"context":0,"support":9},"ma_question":true,"named_voices":6,"passages":8,"sources":6,"sources_by_kind":{"commentary":5,"registry":1}},"title":"The oligometastatic definition and recurrence interval determine what clinicians regard as new"},{"id":"F5","structure":{"claims":8,"claims_by_group":{"comparisons":1,"experience":0,"questions":2,"restated":3,"views":2},"has_counterview":false,"limitations":3,"links":{"context":1,"support":8},"ma_question":true,"named_voices":5,"passages":7,"sources":4,"sources_by_kind":{"commentary":3,"registry":1}},"title":"Radiation inclusion is valued, but adjuvant intent and the pre-MDT dose remain separate questions"},{"id":"F6","structure":{"claims":5,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":1,"views":2},"has_counterview":false,"limitations":3,"links":{"context":0,"support":5},"ma_question":true,"named_voices":2,"passages":2,"sources":2,"sources_by_kind":{"commentary":2}},"title":"Distant relapse supports a systemic-treatment rationale, while technical details remain important to interpretation"}],"medical_affairs_question":"Which PE-PE-like patients warrant added systemic treatment, and when is MDT-first deferral reasonable given toxicity and unestablished survival or quality-of-life benefit?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Support for addition is not proof of every component or downstream benefit"},{"id":"section-2","level":2,"title":"Systemic-treatment deferral has a restrictive clinical condition"},{"id":"section-3","level":2,"title":"Toxicity qualifies the decision to add systemic treatment"},{"id":"section-4","level":2,"title":"Population definition and later recurrence shape the perceived contribution"},{"id":"section-5","level":2,"title":"Radiation inclusion and the pre-MDT dose answer different questions"},{"id":"section-6","level":2,"title":"Distant relapse motivates integration, but local-treatment detail still matters"},{"id":"section-7","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase2","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":5},{"id":"F3","shared_claims":4},{"id":"F6","shared_claims":2}],"id":"T1","label":"Primary endpoint: Relapsed Free Survival (RFS)"},{"findings":[{"id":"F3","shared_claims":1},{"id":"F6","shared_claims":3}],"id":"T2","label":"Secondary endpoint: Distant Relapsed Free Survival (Distant RFS)"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F3","shared_claims":2},{"id":"F6","shared_claims":1}],"id":"T3","label":"Secondary endpoint: Overall Survival (OS)"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F3","shared_claims":5},{"id":"F6","shared_claims":1}],"id":"T4","label":"Secondary endpoint: Safety Endpoint"},{"findings":[{"id":"F6","shared_claims":1}],"id":"T5","label":"Secondary endpoint: Local Progression Disease (Local PD)"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":8},{"id":"F5","shared_claims":4},{"id":"F6","shared_claims":1}],"id":"T6","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":6},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":2},{"id":"F5","shared_claims":6},{"id":"F6","shared_claims":2}],"id":"T7","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F3","shared_claims":5},{"id":"F6","shared_claims":1}],"id":"T8","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":6},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":1},{"id":"F6","shared_claims":1}],"id":"T9","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-29T20:03:43.852812Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-29T20:13:16Z","record_hash":"9d4ac48e0b7f6364c499a6d990517139662a770615b74dbc18bb82a461fb9209","release_hash":"d5bb971a8cb6cdbed88a42b0abb3c335e0504e1cc0f08c6fdc81a827717574c7","report_id":"erudio-nct05578664","run_id":"05e21181-a143-4656-abcf-d9afa451c73f","schema_version":"5.0","slug":"pe-pe-05578664","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"PE-PE asks whether adding pembrolizumab to metastasis-directed surgery or radiotherapy delays relapse in oligometastatic clear-cell kidney cancer. An X poster supports addition but questions sequencing, while an X poster describes systemic-treatment deferral as selective. An X poster welcomes the randomized question yet regards overall-survival and quality-of-life benefits as unresolved. Local-treatment technique and disease history remain questions raised on X. The sources place PE-PE’s phase II results at ESMO 2026.","meta_description":"30 sources screened · 35 verified statements (24 from clinicians verified by NPI or staff page) from 14 sources · 6 findings. Updated Oct 29, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-42c06df1b99fe9f8f3c2","claim-39777f5ed780c1ec94ef"],"id":"F5","paraphrase":"An X poster asks what a pembrolizumab dose given before surgery or stereotactic radiotherapy contributes in PE-PE.","source_channel":"x_thread","source_date":"2026-10-25","title":"Radiation inclusion is valued, but adjuvant intent and the pre-MDT dose remain separate questions"},{"cited_claim_ids":["claim-6d308ef04d5dc1246042","claim-a6c6eadf00551d3907ff","claim-31ba33e916307ce6e126"],"id":"F6","paraphrase":"An X poster asks about radiotherapy dosing, site-specific information and local versus distant recurrence in PE-PE. The thread also asks about previous systemic treatment and the timing and extent of the initial metastatic presentation.","source_channel":"x_thread","source_date":"2026-10-26","title":"Distant relapse supports a systemic-treatment rationale, while technical details remain important to interpretation"}]},"publication":{"approved_at":"2026-10-29T20:13:16Z","approved_by":"Erudio publisher","corrections":[{"affected_ids":[],"date":"2026-10-29T22:21:17Z","summary":"Corrected to match the delivered report: the limitations; the sample findings. The page names the trial's tested drugs (pembrolizumab) and indication (oligometastatic renal cell carcinoma)."}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":30},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","For 1 recording, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.","Some clinician views in the sources used in this report are not yet captured as evidence in this edition.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","17 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The report describes public discussion in the sources reviewed for this edition, not all HCP views or the frequency of any view. Cross-platform copies and reposts do not establish additional independent endorsements.","An audiovisual item's wording was available only from an initial transcript and could not be checked against a fuller transcript.","No full protocol document, exact-trial results publication or exact regulatory label for the pembrolizumab-plus-MDT regimen is included. The reported outcomes remain presentation-based commentary, and comments about indications do not establish regulatory status.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","The endpoint terminology differs between a speaker's PFS wording and the registry's RFS wording. Another speaker's eight-cycle description also differs from the nine-cycle regimen described by the registry and another speaker; neither discrepancy is silently resolved.","Post dates identify when statements were shared, not when a session or readout occurred, and do not demonstrate a change in a speaker's opinion.","Not yet captured in this edition: a view on oligometastatic eligibility thresholds and relapse-free survival with pembrolizumab plus metastasis-directed treatment."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":1,"linkedin_post":1,"other":0,"podcast":0,"publication":0,"registry":1,"regulatory":0,"x_thread":11,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":13,"methods":1},"count":14,"evidence_window":{"end":"2026-10-28","start":"2023-04-05"},"retrieval_snapshot":"2026-10-29T19:26:37.577085Z","timeline":[{"count":1,"week":"2023-W14"},{"count":10,"week":"2026-W43"},{"count":3,"week":"2026-W44"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT05578664:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT05578664:context","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-mmq2caobcgxv5mmlcomg5fpr-3myorbqz2st2e","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-zwaxkm7x44me7z7nwpagim42-3my7sofvlmq2k","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7520035267580354560","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1643551138820636673:519d79ed-8092-4bb1-b62d-ec7bd884c8f3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1751391074910613546:b90f2439-63e8-4de4-9925-c62371e66798","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1768185687876972982:bf0356d7-f444-401d-a60d-50ece489504b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1996755288524013763:02299e30-7fce-42c6-919b-c8fed023744d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2104665265187311756:edf6d04d-1629-4319-9374-81fc0fec9a6c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2109595030763487427:37e5e7ea-389b-4237-865f-3c13e71602ab","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112114051333439580:bada42aa-2592-4c65-b06c-6ff619bec2aa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112521101825986695:80b3fc18-0810-48fd-b92b-2b6789f0a20f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113562340708794705:06ae854f-162d-4e73-a0ec-cc886fabf61f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114263950996979819:64f1d79a-8431-4dd7-a504-bf478d0248a9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114265197133078873:add90dc6-a157-48fe-9b6b-9ab773dd0373","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114265443040919772:481b3654-4063-4a35-88e4-4dba23b52835","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114265699082268880:13724ae6-a854-4c2e-8803-fc5cfa6440ff","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114265930423230599:8958fea9-2beb-4b73-ba1a-51f81367d5d2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114266255045583141:b522397c-465b-46d6-b585-9363df15d7d8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114269490410074525:ec576990-4480-4427-89cc-90f01a422c86","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114271879607230828:102b18c3-b9fd-4cda-bdcd-376e672f7333","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114313342320009702:dfea9905-89af-4696-bd6c-a709383a3861","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114373742935564482:6b1e762e-9037-4aef-9328-fa63024d595d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114382751881220440:3c29fd00-62da-450d-8691-01fa21e7fe45","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114692405836574951:d3f6f0f0-3b30-47e6-8ecb-3aae6a5a1838","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114848821851131949:1f4133a9-5942-4f8a-b54c-ab4e2c847216","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114969279976378740:a3911b4d-472b-42e0-99d8-ce1a10eca5a5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115065811245093037:06354abb-7c7e-4054-bb7e-e781765dbcc9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115878742484795630:0acadad0-c139-464f-94d2-08f00d2d73f8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_video:1751391074910613546","quote_policy":"short_quote_link_out"},{"id":"mcp:x_video:2099082835449516061","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":2,"linkedin_post":1,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":25,"x_video":2,"youtube":0},"by_evidence_role":{"commentary":30},"count":30,"evidence_window":{"end":"2026-10-29","start":"2023-04-05"},"retrieval_snapshot":"2026-10-29T19:26:37.940517Z","timeline":[{"count":1,"week":"2023-W14"},{"count":2,"week":"2024-W04"},{"count":1,"week":"2024-W11"},{"count":1,"week":"2025-W49"},{"count":1,"week":"2026-W37"},{"count":1,"week":"2026-W40"},{"count":1,"week":"2026-W42"},{"count":17,"week":"2026-W43"},{"count":6,"week":"2026-W44"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: pembrolizumab injection plus metastasis directed treatment (surgery or rt)","status":"unmapped"},{"reason":"Unmapped registry intervention: tumor resection or rt","status":"unmapped"}],"indications":[{"reason":"Unmapped registry condition: Oligometastatic Renal Cell Carcinoma","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":"PE-PE","aliases":["PE-PE","Efficacy of PErioperative PEmbrolizumab Treatment in Patients With Resectable Metastases From Kidney Cancer","Efficacy of PErioperative PEmbrolizumab Treatment in Patients With Resectable Metastases From Kidney Cancer. (The PE-PE Study)."],"brief_title":"Efficacy of PErioperative PEmbrolizumab Treatment in Patients With Resectable Metastases From Kidney Cancer","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Oligometastatic Renal Cell Carcinoma"],"display_condition":"oligometastatic renal cell carcinoma","display_interventions":[["pembrolizumab"]],"enrollment":{"count":85,"type":"ACTUAL"},"interventions":[{"name":"Pembrolizumab injection plus metastasis directed treatment (surgery or RT)","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Tumor resection or RT","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"OTHER"}],"nct_id":"NCT05578664","official_title":"Efficacy of PErioperative PEmbrolizumab Treatment in Patients With Resectable Metastases From Kidney Cancer. (The PE-PE Study).","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE2"],"primary_completion_date":{"date":"2028-03","type":"ESTIMATED"},"primary_endpoints":[{"description":"The length of time from the randomization and the appearance of radiological progression of kidney cancer in patients who received pembrolizumab compared to those who did not","measure":"Relapsed Free Survival (RFS)","timeFrame":"24 months"}],"registered_date":{"date":"2022-10-13","type":"ACTUAL"},"registry_last_updated":"2026-10-21","registry_url":"https://clinicaltrials.gov/study/NCT05578664","short_name":"PE-PE","short_name_basis":"registry_acronym","sponsor":"Consorzio Oncotech","start_date":{"date":"2023-03-14","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase2","study_ids":[{"id":"PE-PE","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}